Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Mabpharm Limited ( (HK:2181) ).
Mabpharm Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 18, 2025, in Shanghai. Key agenda items include the consideration of the company’s audited financial statements for 2024, re-election of several directors, re-appointment of Ernst & Young as auditors, and a proposal to authorize the company to repurchase up to 10% of its issued shares. This announcement reflects the company’s ongoing governance and strategic financial management, potentially impacting shareholder value and market confidence.
More about Mabpharm Limited
Mabpharm Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs in the field of oncology and autoimmune diseases.
YTD Price Performance: 76.79%
Average Trading Volume: 717,190
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.04B
Find detailed analytics on 2181 stock on TipRanks’ Stock Analysis page.